AbbVie Outlook Bolstered by Obesity Efforts, Dividend Increases Expected

AbbVie's shares have declined by 10% since my October 2025 update. Despite this, the company's strong commercial progress and emerging efforts in the obesity market with its medication, Zynquista, remain promising. AbbVie's 2026 outlook is also expected to be robust, with potential dividend increases.